ViiV submits fostemsavir MAA to EMA
admin 13th January 2020 Uncategorised 0The application is based on results from the BRIGHTE study, in which the drug showed superiority to placebo. More: ViiV submits fostemsavir MAA to EMA Source: News
read moreThe application is based on results from the BRIGHTE study, in which the drug showed superiority to placebo. More: ViiV submits fostemsavir MAA to EMA Source: News
read moreThe situation is being called “totally unacceptable”, with experts demanding “urgent action.” More: December NHS stats show wait times ‘worst on record’ Source: News
read moreAbbVie and Allergan have waited expectantly to seal the deal on their $63 billion merger as international watchdogs took a close look at the combo. Now, they’re almost home free. The EU says it’s prepared to give a green light
read moreBlueprint Medicines won FDA approval for targeted therapy Ayvakit, a first-ever for the company and for the particular kind of stomach cancer it treats. But the green light wasn’t exactly what the company had hoped for—and that puts its plan
read moreEli Lilly is picking up Dermira for $1.1 billion, or $18.75 a share, more than double the value at which it was trading a month ago. Analysts expected the company to pursue oncology assets, but it’s still a smart deal,
read moreOtsuka Pharmaceuticals’ Avanir unit plans to lay off 140 California employees, a public filing shows, just as the ink has dried on its $116 million kickbacks settlement with the feds. The deal followed years of allegations that its Nuedexta marketing
read more© 1994 - 2024 B.M. Pharmaceuticals